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Abstract
Gene-level analysis of ImmunoChip or genome-wide association studies (GWAS) data has
not been previously reported for systemic sclerosis (SSc, scleroderma). The objective of
this study was to analyze genetic susceptibility loci in SSc at the gene level and to determine
if the detected associations were shared in African-American and White populations, using
data from ImmunoChip and GWAS genotyping studies. The White sample included 1833
cases and 3466 controls (956 cases and 2741 controls from the US and 877 cases and 725
controls from Spain) and the African American sample, 291 cases and 260 controls. In both
Whites and African Americans, we performed a gene-level analysis that integrates association statistics in a gene possibly harboring multiple SNPs with weak effect on disease risk,
using Versatile Gene-based Association Study (VEGAS) software. The SNP-level analysis
was performed using PLINK v.1.07. We identified 4 novel candidate genes (STAT1,
FCGR2C, NIPSNAP3B, and SCT) significantly associated and 4 genes (SERBP1, PINX1,
TMEM175 and EXOC2) suggestively associated with SSc in the gene level analysis in
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White patients. As an exploratory analysis we compared the results on Whites with those
from African Americans. Of previously established susceptibility genes identified in Whites,
only TNFAIP3 was significant at the nominal level (p = 6.13x10-3) in African Americans in
the gene-level analysis of the ImmunoChip data. Among the top suggestive novel genes
identified in Whites based on the ImmunoChip data, FCGR2C and PINX1 were only nominally significant in African Americans (p = 0.016 and p = 0.028, respectively), while among
the top novel genes identified in the gene-level analysis in African Americans, UNC5C (p =
5.57x10-4) and CLEC16A (p = 0.0463) were also nominally significant in Whites. We also
present the gene-level analysis of SSc clinical and autoantibody phenotypes among Whites.
Our findings need to be validated by independent studies, particularly due to the limited
sample size of African Americans.

Competing interests: The authors have declared
that no competing interests exist.

Introduction
Systemic sclerosis (SSc, scleroderma) [MIM 181750] is an autoimmune disease characterized
by three key features: (1) fibrosis of skin and internal organs, (2) a vasculopathy, and (3) autoantibody production. It is a multiorgan system disease with considerable phenotypic heterogeneity, resulting in a broad spectrum of disease severity. Several genome-wide, ImmunoChip,
and follow-up association studies were conducted to identify SNPs associated with SSc risk [1–
8]. All published studies implemented SNP-level analysis meaning that each SNP was analyzed
separately and those with genome wide level of statistical significance were deemed risk associated. SNP-level analysis is effective for identification of SNPs with strong individual effects,
however, it is underpowered to detect genes carrying multiple SNPs in the same gene of small
or medium effect size [9–11]. In the latter case, gene-level analysis can be beneficial because it
will detect genes with multiple small effect size SNPs as significant even if these genes do not
harbor any individual SNPs significant at the genome-wide level. However, a gene-level analysis has never been applied to SSc.
In this study we performed a gene-level analysis focusing on the data generated by the
ImmunoChip platform. We compared results from the gene-level analysis with the results generated by traditional SNP-level analysis. We also performed a gene-level analysis of ImmunoChip and genome-wide association study (GWAS) data on of African-American SSc patients.
Although based on a relatively small group of patients, this study represents the first report of
genetic analysis of African Americans with SSc. The results of the gene-level analysis of SSc
clinical phenotypes (limited SSc (lcSSc) and diffuse SSc (dcSSc)) as well as autoantibody subsets (anti-centromere autoantibodies (ACA) and anti-DNA topoisomerase I (ATA) autoantibodies) among Whites are also presented.

Materials and methods
The study has been approved by the Institutional Review Boards of the participating US institutions, namely Boston University; Georgetown University; Medical University of South Carolina; University of Alabama, Birmingham; University of California Los Angeles; University of
Michigan; University of Minnesota; University of Washington; University of Pittsburgh; University of Texas Health Science Center, Houston, University of Texas MD Anderson Cancer
Center, Houston, Geisel School of Medicine, Dartmouth College; and ethics committees of the
participating foreign institutions, namely Institute of Parasitology and Biomedicine López-
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Neyra, IPBLN-CSIC, Granada, Spain; University of Florence, Florence, Italy; Hospital Universitario, Madrid, Spain; Valle de Hebrón Hospital, Barcelona, Spain; Hospital de la Santa Creu i
Sant Pau, Barcelona, Spain; Hospital Universitario y Politécnico La Fe, Valencia, Spain; University Hospital San Cecilio, Granada, Spain. All clinical investigation has been conducted
according to the principles expressed in the Declaration of Helsinki. Written informed consent
has been obtained from the participants.
Race of the study participants was self-reported, and we used principal component analyses
to remove race outliers as described below. Details on the White population, genotyping and
quality control can be found in our previously published manuscript [7]. The White sample
included 956 cases and 2741 controls from the US and 877 cases and 725 controls from Spain,
after exclusion of individuals based on quality control (QC) (low call rates, non-European
ancestry, or relatedness). There were 1087 (59%) White patients with lcSSc, 574 (31%) with
dcSSc, 671 (37%) ACA-positive (ACA+), and 347 (19%) ATA+ patients (not all patients could
be classified into two distinct phenotypes or had either ACA or ATA antibodies).
The African American sample, after quality control measures, included 291 cases (56 men
and 235 women) and 260 controls (72 men and 188 women). In line with [12], the distribution
of clinical phenotypes and autoantibody subsets in the African American patient population
was markedly different from that in Whites. There were 82 (28%) patients with lcSSc, 201
(69%) with dcSSc, 21 (7%) ACA+, and 69 (24%) ATA+ among the African American cases (as
with Whites, not all patients could be classified into two distinct phenotypes or had either
ACA or ATA antibodies two patients were not tested for ACA and four for ATA).
ImmunoChip analysis: Genotyping was done by Illumina Infinium single-nucleotide polymorphism (SNP) microarray–ImmunoChip. Genotype calling was done using the Illumina
iScan System and the Genotyping Module (v.1.8.4) of the GenomeStudio Data Analysis software. We applied the following criteria for QC: (1) individuals with call rate <90% were
excluded, (2) markers with call rates  90% were excluded, and (3) markers with allele distributions deviating from Hardy-Weinberg equilibrium (HWE) in controls (p < 1× 10−5) were
also excluded. A total 126,270 markers (101,692 of them with a MAF > 0.1%) passed QC and
were included in the analysis.
The same ImmunoChip platform was used for White and African American populations.
The genotyping rate was 0.988 in the African American sample while the genotyping rate was
0.998 among Whites.
GWAS analysis: We also performed a genome-wide genotyping of both African Americans
and Whites. African Americans were genotyped on the Illumina Omni2.5 BeadChip that features ~2.5 million markers capturing variants down to MAF 2.5% and covers, in particular,
African genetic diversity. The same exact individuals that were successfully genotyped on
ImmunoChip were successfully genotyped on this platform. The genotyping rate after QC was
0.993 in African American population. The quality control for African Americans also
included principal component analysis as implemented in SNP & Variation Suite v.7 (Golden
Helix). The first three principal components were derived for each individual from the African
American sample along with HapMap Phase 2 samples as reference populations. Individuals
deviating for more than 6 SDs from the African ancestry cluster centroid were discarded from
further analysis. We also excluded individuals deviating more than 4 standard deviations from
the cluster centroid. Finally, we excluded duplicate and closely related samples (PIHAT  0.5).
The genome wide genotyping of the White populations has been described previously in
Radstake et al (2010) [3]. In brief, Hap550K-BeadChip was used for US Whites and Illumina
HumanCNV370K BeadChip in Spanish Whites.
For the SNP-level analysis the association statistics was computed via logistic regression
including sex as a covariate for each dataset. For the White samples, meta-analysis combining
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odds ratios (OR) and standard errors (SE) of individual datasets (US and Spanish, so that the
controls in each set were from the same country as cases) was performed by means of the
inverse-variance method under the assumption of a fixed effect as implemented in PLINK
v.1.07. [13].
For the gene-level analysis we used Versatile Gene-based Association Study (VEGAS) [14].
We used VEGAS because it outperforms similar methods by sensitivity and specificity from
simulation studies [15]. VEGAS can be applied to the data generated by any GWAS designs,
including family-based GWAS, meta-analyses of GWAS and DNA-pooling-based GWAS. The
test uses information from the complete set of markers within a gene. To account for linkage
disequilibrium between markers VEGAS uses simulations from the multivariate normal distribution. VEGAS assigns SNPs to autosomal genes according to positions on the UCSC Genome
Browser hg18 assembly. In order to capture regulatory regions and SNPs in LD, the gene
boundaries are defined as ±50 kb of 5’ and 3’ UTRs. VEGAS assigned SNPs genotyped by
ImmunoChip to 11,501 genes. Assuming independence of the gene level tests, the threshold
for statistical significance in the analysis of ImmunoChip in Whites was set to be 4.35x10-6,
and at 2.8x10-6 for the analysis of GWAS data [14]. However, since this threshold is likely to be
conservative given the overlap between genes, we report findings with p-values <10−5. Also,
since the sample size for African Americans was limited, for this population we present findings with the p-value below 10−3, acknowledging that this is a study limitation and that the
analysis is exploratory and is in need for further validation. We use the term “nominal significance” to denote p-values in the range of 0.05 to 10−3, interpreting them as weak evidence of
association. We excluded HLA region from the analysis because it is universally significant.
We used PathwayStudio [16] to build a pathway of known and novel SSc risk-associated
genes. The PathwayStudio uses text mining to identify reported interactions between genes
and build a network based on the known interactions.

Results
ImmunoChip analysis
Table 1 shows results from the gene-level and SNP-level analyses for 19 non-HLA genes previously shown to be associated with SSc in Whites [1–8, 17, 18]. Out of 19 known SSc genes, all
except for SCHIP1, IRF8, and CD247 were nominally significant in the gene-level analysis in
Whites. IRF5, STAT4, and TNPO3 were significant in both the SNP- and gene-level analyses
among Whites.
In the gene-level analysis of clinical phenotypes (S1 and S2 Tables) and antibody subsets
(S3 and S4 Tables), STAT4 was significant for lcSSc and ACA+ patients and TNPO3 in ATA
+ patients. Of the 19 genes examined, only TNFAIP3 was nominally significant in African
Americans in the gene-level analysis.
Table 2 shows non-HLA genes with the p-values below 10−5 in the gene-level analysis for
Whites (excluding those already established in Whites), with the addition of p-values for these
genes in African Americans. The genes with the p-values below 4.35x10-6 are shown in bold.
One gene out of four significant at this level in Whites, namely FCGR2C, was also nominally
significant in African Americans. PINX1, which was only borderline significant in Whites, also
showed a nominal significance in African Americans. Additionally, nominally significant
SNPs where observed in STAT1 and SCT genes and in the borderline significant EXOC2 in the
analysis of African Americans (Table 2), even though these genes did not reach significance in
the gene-level analysis in that population.
The top genes identified for clinical phenotypes and autoantibody subsets are shown in
S1–S4 Tables, in the left portion for the gene-level analyses based on ImmunoChip. FCGR2C,

PLOS ONE | https://doi.org/10.1371/journal.pone.0189498 January 2, 2018

4 / 12

Gene-level association analysis of systemic sclerosis

Table 1. Results of the gene-level analyses for known genes associated with risk of SSc in Whites and African Americans, based on ImmunoChip.
Whites
Gene

African Americans

Chr

NSNPs

P-value

Top SNP

STAT4

2

113

2.00E-09

rs10174238

TNPO3

7

102

3.00E-08

Top SNP P-value

NSNPs

P-value

Top SNP



4.65E-13

108

0.105

rs1551443



Top SNP P-value
0.0106

rs17340351



2.39E-10

105

0.314

rs1495461

§

0.0574
0.0574
0.00742

IRF5

7

49

2.00E-06

rs12534421



7.42E-10

53

0.211

rs1495461

‡

TNIP1

5

124

4.90E-05

rs10463312



4.87E-06

156

0.189

rs2277940

§

IL12RB2

1

69

5.40E-05

rs2201584



1.29E-06

84

0.921

rs11209045



2.99E-08

172

0.552

rs11250139



0.0244



0.00771

0.0418

8

176

1.43E-04

rs2409781



ITGAM

16

53

1.96E-04

rs1143683

†

5.70E-05

67

0.337

rs4561481

IL12RB1

19

42

0.001144

rs2305743



7.23E-05

48

0.215

rs426132



0.0733

TNFAIP3

6

45

0.00145

rs892999

0.0103

69

0.00613

rs10223636



0.00203

IL12A

3

110

0.00248

rs4679867



8.79E-05

141

0.741

rs4679867



0.0508

†

0.1514
0.0083

BLK

TYK2

19

60

0.00363

rs2304256

ATG5

6

54

0.0076

rs11758079

CSK

15

8

0.0129

rs6495122



1.61E-04

63

0.758

rs8108709



0.00276

62

0.272

rs4946731



§

1.96E-05

9

0.787

rs8033381



0.299

5.64E-04

112

0.844

rs3823946



0.0122

0.00699

187

0.755

rs9870786



0.0177

3.09E-04

93

0.597

rs9843169



0.0177

0.00541

8

0.467

rs10918695



0.211

0.0165

28

0.518

rs11642456



0.129

rs17753641





JAZF1

7

96

0.0325

rs6971086



PXK

3

180

0.0397

rs7626140



DNASE1L3

3

84

0.0464

rs4681786



CD247

1

5

0.0821

rs2056626



16

24

0.0986

rs10863202

IRF8
SCHIP1


3

81

0.174

rs1675497




0.00108

77

0.449

0.0543

Intronic SNP


†
§

intergenic SNP
coding SNP

3’ downstream SNP

‡

5’ upstream SNP

https://doi.org/10.1371/journal.pone.0189498.t001

STAT1, and FCGR3B were significant in lcSSc, although FCGR2C and FCGR3B shared the
most significant SNP rs455499 and the gene-level p-value for FCGR2C was more significant
(S1 Table). In dcSSc, three genes (IL34, ABBA-1, and VAC14) were identified as significant,
although they shared the most significant SNP rs11640251 and IL34 had the best p-value in the
gene-level analysis (S2 Table). In ACA+ patients, in addition to STAT4, six genes (FCGR2C,
Table 2. Comparison of novel candidate genes (at p<4.35x10-6 indicated in bold) and suggestive genes (4.35x10-6<p<10−5) detected in Whites to the corresponding
statistics in African Americans in the gene level analysis, based on ImmunoChip.
Whites
Gene

African Americans

Chr

NSNPs

STAT1

2

60

<1.00E-06

rs11893432

FCGR2C

1

26

3.00E-06

NIPSNAP3B

9

3

4.00E-06

SCT

11

34

P-value

4.00E-06

Top SNP

Top SNP p-value

NSNPs

P-value

Top SNP

Top SNP p-value



4.01E-11

58

0.581

rs16833197



rs4554699



2.72E-08

24

0.0158

rs17411858



rs3780540



7.79E-04

4

0.551

rs3780540



0.31

rs4963128



6.72E-05

52

0.691

rs10902178



0.0456

0.0195
0.00497

SERBP1

1

48

6.00E-06

rs3790569



5.61E-05

61

0.855

rs11807749



PINX1

8

200

8.00E-06

rs17152571



1.46E-05

210

0.0283

rs17152345



6.61E-04

EXOC2

6

15

8.00E-06

rs908026



2.79E-05

21

0.382

rs7761186



0.0396



0.0682

Intronic SNP
intergenic SNP



https://doi.org/10.1371/journal.pone.0189498.t002
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Table 3. Genes most significant (at p<10−3) in African Americans in the gene-level analysis and the results for these genes in Whites, based on ImmunoChip.
African Americans
Gene

Chr

NSNPs

P-value

Whites

Top SNP

Top SNP p-value

NSNPs

P-value

Top SNP

Top SNP p-value

SCN4B

11

4

1.20E-05

rs868344

ǁ

4.04E-03

4

0.544

rs671111

§

0.291

SCN2B

11

4

1.50E-05

rs868344

§

4.04E-03

3

0.687

rs671111

§

0.291

MRPL28

16

1

6.20E-05

rs743961

‡

6.72E-05

1

0.0863

rs3848368



TMEM8

16

1

6.20E-05

rs743961



6.72E-05

1

0.105

rs3848368



0.0856

NME4

16

1

6.90E-05

rs743961

‡

6.72E-05

1

0.0869

rs3848368



0.0856

DECR2

16

1

7.50E-05

rs743961

‡

6.72E-05

1

0.0836

rs3848368



UNC5C

4

8

1.22E-04

rs7697199



6.20E-05

6

5.57E-04

rs17381177



RAB11FIP3

16

2

2.96E-04

rs743961

‡

6.72E-05

1

0.358

rs3785301



0.338

PLCG2

16

5

4.97E-04

rs4325546



3.15E-03

8

0.601

rs3936112



0.0874

CLEC16A

16

329

5.29E-04

rs1646066



5.39E-04

355

0.0463

rs16957854



0.00169
0.083

ABCB4

7

24

5.77E-04

rs17149601



2.16E-04

17

0.271

rs17149512

ǁ

TCERG1

5

1

7.61E-04

rs10056189



7.31E-04

1

0.135

rs10056189



PHF19

9

74

8.09E-04

rs1008382



1.32E-04

61

0.721

rs388040

ǁ



0.0856

0.0856
7.84E-04

0.171
0.0426

3’UTR SNP

§

3’ downstream
‡
5’ upstream


intronic SNP



intergenic SNP

https://doi.org/10.1371/journal.pone.0189498.t003

SRCAP, PHKG2, LOC90835, RNF40, and FCGR3B) reached significance in the ImmunoChipbased gene-level analysis, but the middle four genes shared the most significant SNP rs71889
27 and SRCAP showed the best gene-level p-value (S3 Table), and FCGR2C and FCGR3B also
shared the most significant SNP rs455499. Of these two genes, FCGR2C showed a more significant gene-level p-value like in the case of the lcSSc phenotype. Among ATA+ patients, in addition to TNPO3, C16orf68, P2RX1, C3orf25, IFT122, and MBD4 reached significance in the
gene-level analysis, with the last three genes sharing the same most significant SNP rs2307293
(S4 Table).
In the reverse approach we selected top non-HLA genes most significant in African Americans (p<10−3) based on the gene level analysis (Table 3; 13 genes but only 9 independent
regions, due to the gene overlap).
Of these genes, only UNC5C (p = 5.57x10-4) and CLEC16A (p = 0.0463) were nominally significant in the gene-level analysis in Whites, and both these genes and PHF19 harbored a nominally significant SNP in Whites (Table 3).
Among the 63 top genes (27 independent regions) selected based on SNP level analysis in
African Americans (S5 Table; genes with best SNP p-value<10−3 in African Americans), 16
genes (12 independent regions) were also nominally significant in Whites at the gene level and
42 genes harbored at least nominally significant SNPs in Whites (25 different SNPs due to
assignment of some SNPs to several genes at once). Since under the null hypothesis the expected
number of nominally significant SNPs in Whites is ~1 (27x0.05 = 1.3), the results suggest some
overlap in genetic susceptibility loci for SSc between Whites and African Americans.

GWAS data analysis
We performed similar analyses also based on the GWAS genotyping which was, however, performed on different platforms in Whites and African Americans, and this made the results less
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comparable. The results are presented in S6–S11 Tables. In brief, among the genes previously
identified in Whites, in addition to TNFAIP3, ATG5 showed a nominal significance in the
gene-level analysis in African Americans, potentially due to a denser coverage of this gene (81
vs 62 SNPs) on the 2.5 M Omni platform than on ImmunoChip (S6 Table).
Beyond the genes previously established as associated with SSc in Whites, only one gene,
TMEM175, showed a borderline significant association in the gene-level analysis in Whites
(p = 3.0x10-6) in GWAS. Its most significant SNP rs2290405 was shared with two other genes
(SLC26A1 and DGKQ; S7 Table). The analysis of the corresponding genes in the GWAS data
in African Americans did not detect gene-level significance for these genes but TMEM175 harbored a nominally significant SNP rs11946340 unlike the other two neighboring genes.
In the analysis of clinical phenotypes and autoantibody subsets, out of already established
SSc susceptibility genes, IRF5, TNPO3, and IRF8 were significant in lcSSc patients. There were
also seven newly identified genes, of which four (DGKQ, IDUA, TMEM175, and SLC26A1)
shared the same most significant SNP rs11724804; of these, DGKQ showed the best gene-level
p-value. IRF4, CCDC104, and TLR10 were also significant. Notably all these genes were at least
nominally significant in the ImmunoChip-based gene-level analysis, except for CCDC104
which is not on ImmunoChip (S1 Table). In dcSSc, in addition to IRF5 and TNPO3, CPSF4
and ATP5J2 showed significant p-values in the gene-level analysis; they shared the same most
significant SNP rs10235235, and CPSF4 was more significant in the gene-level analysis. Except
for IRF5 and TNPO3, no gene reached statistical significance in the ACA+ subset in the
GWAS-based gene-level analysis. In the ATA+ subset, TLR10 and TLR1, sharing the same
most significant SNP rs10024216, were significant (both reached only nominal significance in
the ImmunoChip-based gene-level analysis) (S4 Table).
In the reverse analysis, considering the top genes identified in the gene-level analysis in
African Americans (12 non-HLA genes but 11 regions due to the gene overlap, S8 Table),
none of the corresponding genes was even nominally significant in Whites but 6 genes harbored nominally significant SNPs. Among the genes identified in the GWAS SNP-level analysis on African Americans as harboring most significant SNPs (p<10−3; 488 such genes but
only 308 independent regions because of the gene overlap), 311 genes (255 independent
regions) also harbored at least nominally significant SNPs in Whites. Eight genes (SLC2A13,
NRG3, SLC10A7, MKL1, DZIP1L, C8orf58, KIAA1967, and HDAC1; seven independent
regions, C8orf58 and KIAA1967 representing the same region) were nominally significant in
both Whites and African Americans in the gene-level analysis. The results are presented in S9
Table (a). Five SNPs—rs2994241 in C10orf27/ADAMTS14, rs6025407 in BMP7, rs6796265 in
OSBPL10, rs7734699 in MRPS27, and rs6075784 in STK35 –were nominally significant in both
Whites and African Americans. These five SNPs are marked in green in S9 Table (a), and their
risk effects are shown in S9 Table (b).
We also catalogued genes identified in African Americans either in GWAS or ImmunoChip
gene-level analysis (S10 Table), or by the top SNP p-value (with p<10−3) (S11 Table). In the
few cases where the same SNP was top in both GWAS and ImmunoChip analyses, a slight pvalue variation is explained by the QC procedures that eliminated different number of individuals from the ImmunoChip versus GWAS analysis.
Genes for SSc and other autoimmune diseases are enriched by the immune response genes
[19–21]. One can expect, therefore, that SSc genes will be often involved in direct interactions.
We used PathwayStudio to build an interaction network of known as well as 6 novel candidate
genes (both significant and suggestive) (Table 3) identified by the gene-level analysis. Such networks may be useful by providing guidance to explore biological mechanisms underlying SSc
risk. We found that two suggestive candidates, namely EXOC2 and PINX1, interact with
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known genes associated with risk of SSc. The EXOC2 protein has been shown to bind LST1
[22], and PINX1 and STAT1 show protein/protein interaction [23] (S1 Fig).

Discussion
We identified 4 novel candidate genes (STAT1, FCGR2C, NIPSNAP3B, and SCT) significantly
associated and 4 genes (SERBP1, PINX1, TMEM175 and EXOC2) suggestively associated with
SSc in a gene level analysis in Whites. Some of these genes have been shown to be directly
involved in immune response. For example, FCGR2C encodes a member of low-affinity immunoglobulin gamma Fc receptors. FCGR2C is found on the surface of many immune response
cells. The gene encodes a transmembrane glycoprotein involved in phagocytosis and clearing
of immune complexes. A suggestive novel gene, SERBP1, encodes a B-cell antigen, shown to
predict anti-tumor immune response [24]. Another suggestive gene, EXOC2, is associated with
innate immunity and has been shown to play a role in susceptibility to Crohn’s disease [25].
We note that the suggestive signal at EXOC2 overlaps with the signal at IRF4 previously
described in the cross-disease meta-GWAS of SSc and rheumatoid arthritis [26], which points
at the importance of this region in autoimmune conditions. This gene harbored a SNP rs908
026 with a relatively strong statistical evidence for risk association (P = 2.8x10-5). Risk-associated SNPs were observed in other gene-level candidates as well. For example, rs11893432
(STAT1 gene; p = 4.01x10-11) and rs4554699 (FCGR2C gene; p = 2.7x10-8) were significant at
the GWAS level. The most significant SNPs in other novel candidates were: rs2290405 in
TMEM175 (p = 1.82x10-6), rs17152571 in PINX1 gene (P = 1.5x10-5), rs3790569 in SERBP1
gene (P = 5.6x10-5), rs4963128 in SCT gene (P = 6.7x10-5), and rs3780540 for NIPSNAP3B
gene (P = 7.8x10-5). We admit that a further revalidation in an independent study of SSc in
Whites is necessary.
Out of the 19 genes that were previously identified as harboring SSc susceptibility SNPs in
Whites, only TNFAIP3 was nominally significant in the gene-level analysis in African Americans. Previously, we showed that SNPs of TNFAIP3 had a strong association with expression of
matrix metalloproteinase 1 and 3 in fibroblasts of ethnically diverse patients in response to silica particle stimulation [27].
Several factors could have contributed to the absence of an association in African Americans for genes found in Whites. First, the distribution of clinical phenotypes is markedly different in the two populations, with a considerably higher proportion of the diffuse phenotype
among African Americans (69%) as compared to Whites (31%). Our previous publication [6]
shows differences in the genetic architecture of SSc clinical phenotypes. Thus clinical phenotype-specific analyses by ethnic group would be most meaningful, because they would allow
for more accurate racial comparisons. Unfortunately, the limited number of African American
participants precluded the phenotype or autoantibody subset analyses in the current study.
Second, the power of the analysis in the African Americans was limited because of the sample size. Moreover, the power of the analysis depends not solely on the sample size but also on
the risk allele frequency. S9 Table (b) exemplifies that there is a considerable variation in the
allele frequencies between the two populations, which could have contributed to the inter-ethnic differences. Third, even if the effects of causal SNPs are similar across ethnicities, GWASidentified tagging SNP alleles can be in the opposite linkage phases in two given ethnic groups.
This will result in the opposite effects of the tagging SNPs identified as significant in both African Americans and Whites, and the data in S9 Table (b) suggest exactly that: some SNPs identified as nominally significant have very similar frequencies but the opposite direction of the
effect in African Americans and Whites. It is also possible that the causal SNPs are different in
different ethnicities although the susceptibility genes are the same. A gene-level analysis of
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dense genotyping data, such as ours, should be able to capture the susceptibility genes even in
case of the ethnic heterogeneity for causal alleles, unless a given ethnicity lacks causal variants
in a potential susceptibility gene, in which case the gene will not be associated with disease in
that ethnic group. The genes listed in Table 2, except for NIPSNAP3B, are densely SNP-genotyped in both Whites and African Americans. Thus it is not very likely that an individual SNP
being poly- versus monomorphic has led to the loss of an association. For NIPSNAP3B, the top
SNP in both populations was the same, rs3780540, and the MAF was actually higher in African
Americans (0.116) than in Whites (0.0179), yet it was only significant in Whites.
An interaction network built using Pathway Studio detected a large number of interactions
between genes associated with SSc risk. Genes with the largest number of interactions include
ITGAM, AIF1, STAT1, IL12RB2; these genes form hubs of the network and are likely to be
master genes in biological control of SSc risk. Two suggestive candidates, EXOC2 and PINX1,
are also part of this network.
As mentioned before, limitations of this study are (1) a relatively small sample size for African Americans, which prevents us from drawing any definite conclusion concerning the hitherto unresolved issue whether the same genes/SNPs influence SSc risk in different ethnic
groups, and (2) the absence of independent validation cohorts. We acknowledge, therefore,
that our analyses should be considered exploratory. Nevertheless, we carried out such analyses
because the data are unique and their analysis may be important for the understanding of the
role of ethnicity in the genetic architecture of SSc.
The results of our exploratory analysis might suggest that there exist both trans-racial and
race-specific susceptibility loci for SSc, but further validation by independent studies, in particular a properly powered SSc GWAS in African Americans that allows subset analyses, is necessary to answer this question.

Conclusions
A gene-level analysis focusing on the data generated by the ImmunoChip platform was performed on White and African American SSc patients. This study represents the first report of
genetic analysis of African Americans with SSc. The gene-level analysis identified four novel
candidate genes (STAT1, FCGR2C, NIPSNAP3B, and SCT) significantly associated with SSc in
Whites. As an exploratory analysis we compared the results in Whites with those generated
from African Americans. There was weak evidence of existence of SSc susceptibility loci that
showed effects in both Whites and African Americans. Our findings need to be validated by
independent studies, particularly due to the limited sample size of African Americans. The
clinical phenotype and autoantibody subset analyses for Whites are also presented, but future
studies should compare the phenotype- and autoantibody-stratified analyses in Whites and
African Americans.
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